Within a few months of the introduction of isoniazid (isonicotinic acid hydrazide) in the treatment of pulmonary tuberculosis, reports appeared of the frequent and rapid emergence of isoniazidresistant bacteria when the drug was used alone (Medical Research Council, 1952; Ferebee and Long, 1953; Lotte and Poussier, 1953; U.S. Veterans Administration, 1953) . In view of earlier experience with streptomycin (Medical Research Council, 1948; Ferebee and Appel, 1951) , this was regarded as an undesirable feature of isoniazid therapy. First it was presumed that a patient yielding resistant organisms would derive no further, or at best reduced, benefit from continued treatment with the drug. Secondly there was a risk that contacts might be infected with isoniazid-resistant organisms. In Great Britain, as a consequence, the widespread use of isoniazid alone stopped, and research was directed to the prevention of isoniazid resistance by the use of other anti-tuberculosis drugs in combination with isoniazid. Various combinations have since been shown to reduce considerably the incidence of isoniazid resistance (Medical Research Council, 1953c , 1955 Pitts, Tempel, Miller, Sands, Fitzpatrick, and Weiser, 1953;  U.S. Public Health Service, 1953; U.S. Veterans Administration, 1953 Administration, , 1954 .
It has been suggested that bacterial resistance to isoniazid may in some patients be transitory (Ashino, 1953; Petit, 1953a and b; Ogilvie, 1954) .
Other data, however, show little evidence of a general reversion of resistant strains towards sensitivity over a period of at least six months after stopping treatment with isoniazid (Medical Research Council, 1954) . It has also been shown that organisms which are highly resistant to isoniazid may be of low pathogenicity in some animal species (Barnett, Bushby, and Mitchison, 1953; Barry, Conalty, and Gaffney, 1953; Middlebrook and Cohn, 1953; Meissner, 1954; Mitchison, 1954 ), but it is not known whether this applies in man. Because the strains do not rapidly return to sensitivity and because their pathogenicity may have altered, it is important to examine the clinical progress of patients in whom isoniazid-resistant organis rs have emerged.
A preliminary study of the clinical significance of isoniazid resistance was made in the first report of the Medical Research Council isoniazid trial (1952) , but the bacteriological information was then far from complete. A full study over a three-month period, derived from the complete information for all patients who received isoniazid alone in that trial, is now presented. The essence of this study has been to divide the patients into groups based upon the results of cultures and sensitivity tests after two months' treatment in the trial, and to compare the clinical progress of the groups over the three-month period.
Details of the organization of the isoniazid trial were given in the first two reports (Medical Research Council, 1952 ; the list of hospitals, and the names of the clinicians, bacteriologists, and ~~~WALLACE FOX and MAN SUTHERLAND GROup 3.-Chronic forms of pulmonary tuberculosis expected to make only a limited response to streptomycin plus P.A.S.
Direct examinations of the sputum, cultures, and sensitivity tests were routinely performed on entry to the trial, and at monthly intervals thereafter, using standardized techniques (Medical Research Council, 1953b Since, as with streptomycin (Steenken, 1949) (Table Il) . On the other hand there is a slight suggestion in each cavitation category that substantial (2-plus or 3-plus) improvement was more frequent in the moderately resistant group, and substantial deterioration more frequent in the strongly resistant group.
To summarize, this study of radiographic changes has demonstrated differences between the threemonth progress of the patients when grouped according to the bacteriological results at the end of two months. Thus, the standardized percentages showing radiographic improvement were 75% for the negative group, 55% for the positive-sensitive group, and 46% for the positive-resistant group.
The negative group, in other words, fared substantially better than the patients with positive cultures, whether the strains were sensitive or resistant. To appraise the clinical significance of the emergence of isoniazid-resistant organisms a detailed comparison is made in the following sections of the clinical progress of the patients in the positivesensitive and positive-resistant groups. Although it is probable that the negative group consists largely of patients with sensitive strains, this group cannot fairly be included in the comparison because of the likelihood that the patients will have smaller bacterial populations, on the average, than the patients with positive cultures at two months. It is relevant to note that of the patients with negative cultures at two months (26%) yielded a positive result on direct examination at one month, and only 9% at three months, compared with 61% and 54% respectively of those with positive cultures at two months.
TIMING OF RADIOGRAPHIC CHANGES IN PATIENTS WITH SENSmVE AND WITH RESISTANT CULTURES.-When the independent radiographic assessment for the three-month period was undertaken, three radiographs were used, namely on entry to the trial, at the end of two, and at the end of three months. An assessment was first made over the whole three months and was then apportioned between the first two months and the third month. It is thus possible to investigate when during the three-month period the radiographic changes occurred in the resistant and in the sensitive group of patients. The results of this investigation are presented in Table Ill , which shows that in each period radiographic improvement occurred less frequently in the resistant group of patients. For example, of 24 patients in the sensitive group with 2-plus cavitation initially, 58% improved in the first two months and 42% in the third month. The corresponding figures for the 38 patients in the resistant group were 34% and 26%. This pattern is confirmed by the standardized percentages showing improvement, which are in each period less for the resistant than for the sensitive group. In each period, too, a larger proportion of patients deteriorated in the resistant than in the sensitive group. It will be observed, further, that in the third month, when a greater disadvantage might have been expected from the development of isoniazid resistance, the contrast between the resistant and sensitive groups was very similar to that in the first two months. It may be concluded that the disadvantage to the resistant group of patients applied in each period separately.
Since it has been stated that patients frequently deteriorate at the time of, or soon after, the detec tion group.bmj.com on June 25, 2017 -Published by http://thorax.bmj.com/ Downloaded from of isoniazid resistance (Joiner, MacLean, Pritchard, Anderson, Collard, King, and Knox, 1952; Coates, Meade, Steenken, Wolinsky, and Brinkman, 1953; Gemez-Rieux, 1953 ), a more detailed study has been made of the records of all the 23 patients who showed radiographic deterioration in the first two months, in the third month, or in both periods; three were culture-negative at two months, four were in the sensitive group, and 16 were in the resistant group (Table IV) . Of the 11 patients in the resistant group who showed radiographic deterioration in the first two months, two deteriorated further in the third month, but seven showed no change and two actually improved. The remaining five of the 16 patients in the resistant group deteriorated only in the third month; however, so did three of the seven patients with sensitive or negative results at two months. These figures do not show that the deteriorations in the resistant group occurred principally in the third month, as might have been expected if deterioration was the direct result of a loss of chemotherapeutic effectiveness due to the development of bacterial resistance. Bearing in mind that the first period is twice as long as the second, the deteriorations-11 against 7-appear to be fairly evenly divided between them.
Although there was no independent assessment of radiographic change in the first month, the monthly progress reports from the clinicians in charge of the patients provide further information on the timing of the deteriorations. Among the 11 patients in the resistant group for whom deterioration was reported by the assessor at two months, radiographic deterioration was reported by the clinician in the first month for four, in the second month for one, and in both months for two patients. The timing of these changes also provides no evidence that radiographic deterioration was a consequence of the emergence of isoniazid resistance.
In summary, this study of the radiographic assessments during the three-month period indicates that, when allowance is made for the extent of cavitation present at the start of treatment, the patients who yielded resistant organisms at the end of two months had not responded so well as those with sensitive organisms. There is, however, no evidence from the timing of the radiographic changes that the emergence of isoniazid-resistant strains was responsible for the difference. It is possible that in the resistant group the less satisfactory radiographic progress and the development of isoniazid resistance are both characteristics of patients with a particular host response or type of disease, perhaps associated with a large bacterial population. AND IN TEM-PERATURE IN THE THREE-MONTH PERIOD RELATED  TO BACTERIOLOGICAL RESULTS AT THE END OF Two MONTHS The changes in the sedimentation rate during the three months of isoniazid therapy were also examined according to the extent of cavitation at the start of treatment and the bacteriological findings at the end of two months. The results are summarized in Table V . Among patients with a sedimentation rate of 21 mm. or more initially, the standardized percentages with a normal sedimentation rate (0-10 mm.) at the end of three months were 35% for the negative and 19% for the positive group, showing a substantial, and statistically significant, benefit to the negative group. (When these percentages were standardized in addition for the general condition, the sedimentation rate and the average evening temperature at the start of treatment, they were essentially unaltered, being 32% and 20% respectively.) In contrast there was only slight evidence that the patients with sensitive cultures at two months had responded better than those with resistant cultures, the percentages being 21% and 16% respectively. The unimportance of this difference is emphasized by the results for the patients with strongly resistant organisms, who showed as favourable a response (22%) as the sensitive group (21%). Study of the few patients in whom the sedimentation rate had risen by the end of three months, and a detailed investigation of the changes month by month, showed no evidence that the development of bacterial resistance influenced the sedimentation rate.
CHANGES IN SEDIMENTATION RATE
Corresponding studies of temperature offered no evidence of a relation between the development of bacterial resistance and temperature response.
BACTERLAL CONTENT OF SPUTUM IN THE THREE-MONTH PERIOD RELATED TO RESULTS OF SENSITIVITY
TESTS AT THE END OF TwO MONTHS A further study of the progress of the groups of patients with sensitive and with resistant strains at the end of two months was made by investigating the bacterial content of the sputum at one, two, and three months. The results after three months are shown in Table VI of those with resistant strains. Thus the bacteriological responses of the sensitive and resistant groups differed substantially at the end of three months' treatment, the difference being apparent for each degree of initial cavitation. It will be noted, however, that the responses of the patients with moderately and with strongly resistant strains were very similar. Because of these differences between the sensitive and resistant groups at three months, it was important to undertake corresponding investigations of the bacterial content of the sputum at one month and at two months to see when the difference emerged. (It was not possible to compare the findings during treatment with those at the start, because the pre-treatment bacteriological result which was submitted for each patient was usually the most positive result from a series of tests, and so was not representative.) The results at one, two, and three months are summarized in the upper part of Table VII. In the sensitive group, the standardized percentages of patients with a positive direct examination were 61% at one month, 30% at two months, and 27% at three months. In the resistant group the corresponding figures were 71%, 62%, and 65%. At one month there was thus no great difference between the results in the two groups. By two months the sensitive group had shown a substantial fall in the frequency of positivity, whereas in the resistant group the percentages at two and three months remained nearly as high as at one month. A further study was therefore undertaken of this difference between the resistant and sensitive groups.
First, considering the 85 patients with a resistant result at two months, the group contained 24 patients who had already given a resistant result at one month (13 yielded resistant and 11 doubtful, probably resistant, results), and 48 patients with a sensitive result at one month. (Of the remaining 13 patients, nine had a negative culture and four no test at one month.) The bacteriological results for these two subgroups of patients at one, two, and three months are summarized in the lower part of Following the introduction of isoniazid, it was soon found that among patients with positive cultures after three months' treatment with isoniazid alone, approximately two-thirds had organisms resistant to the drug (Medical Research Council, 1952; Ferebee and Long, 1953) . It is therefore important to establish whether the emergence of isoniazid-resistant bacteria is accompanied by a loss of clinical effectiveness of the drug. A preliminary analysis of the data from the Medical Research Council isoniazid trial indicated that, as with streptomycin (Medical Research Council, 1948) , resistance to isoniazid developed more readily in patients acutely ill at the start of treatment. When the progress of patients with similar pretreatment characteristics was studied for a period of three months, it was found that those with drugresistant organisms had fared, as a group, less well than those not known to have drug-resistant organisms. The bacteriological information in that report (Medical Research Council, 1952) was, however, far from complete.
The present report is based upon the complete information for 234 patients in that trial who received isoniazid alone for a period of three months, and consists of two main studies. there was a notable difference between the clinical progress of patients who were culture-negative at two months and those who were culture-positive. After three months' treatment the responses in radiographic appearances and also in the sedimentation rate were better for the negative group. These differences persisted when allowance was made for the initial clinical differences between the groups. Further study of the group with positive cultures at two months shows that, when allowance was made for the extent of initial cavitation, patients with isoniazid-resistant organisms were radiographically at a disadvantage at the end of three months' treatment compared with those with sensitive organisms. The difference just attains statistical significance. The data suggest, however, that this difference may not be a direct consequence of the development of bacterial resistance. If the relationship were causal it would have been expected that the lack of radiographic improvement in the resistant group would have been apparent towards the end of the three months rather than earlier, and this was not so. The available evidence also suggests that the radiographic deteriorations were evenly divided among the three months. It thus remains uncertain whether the radiographic disadvantage shown by the patients who had developed resistant organisms at the end of two months is a direct consequence of the emergence of resistant strains or whether poor radiographic progress and the development of resistance to isoniazid (used alone) are both characteristics of patients with a particular host response or type of disease. Cohen (1954) , in an editorial article based upon unpublished data of the U.S. Public Health Service Cooperative Investigation, has reached a similar conclusion.
Changes in the sedimentation rate and in the temperature in the resistant and sensitive groups were similarly studied. There is little evidence that the course of either was affected by the development of bacterial resistance.
When the resistant group was subdivided, there was no evidence that the three-month radiographic or clinical progress of the patients with strongly resistant organisms at the end of two months had differed from that of patients with moderately resistant organisms.
The apparent discrepancy between these inconclusive findings concerning isoniazid resistance and those in the interim report of the isoniazid trial (Medical Research Council, 1952 ) is readily resolved. Owing to the comparatively small number of sensitivity results which were available when the interim report was prepared, the progress of the patients known to have resistant cultures at the end of two months was compared with that shown by all the remaining patients; but many of these were later found to be culture-negative at two months. The results of the present more complete analysis indicate that the differences which emerged in the earlier report were essentially differences between patients with positive and with negative cultures, not between patients with resistant and with sensitive cultures.
In the present report the results of the monthly sputum examinations have also been studied in relation to the development of resistance. Although the percentage of patients with specimens positive on direct examination at three months was much higher in the resistant than in the sensitive group, a study of the figtures month by month showed no evidence of changes in bacterial content of the sputum, associated with the development of bacterial resistance. It is possible that an initial difference between the resistant and sensitive groups, either in the size or the character of the bacterial population, may be the explanation of the differences during the three-month period. Because of the nature of the available bacteriological data, no direct comparison of the bacterial content of the sputum in the resistant and sensitive groups was possible at the start of treatment. There may also have been some difference in host resistance in the two groups at the start of treatment.
There have been a number of reports of clinical, bacteriological, or radiographic deterioration, or of failure to improve, associated with the emergence of isoniazid-resistant strains (Joiner and others, 1952; Berg, Herholz, and Meissner, 1953; Berg and Meissner, 1953; Coates and others, 1953; Gernez-Rieux, 1953; Lotte and Poussier, 1953) .
However, none has presented adequate evidence that the patients relapsed as a consequence of the emergence of the isoniazid-resistant organisms. Lotte and Poussier (1953) demonstrated the association between initial clinical condition and the subsequent development of resistance, and recognized the consequent limitations of their data.
The present analysis has shown clearly that a study of the clinical significance of the emergence of organisms resistant to a drug in the treatment of pulmonary tuberculosis presents many problems, and these will now be discussed.
It has often been demonstrated (Medical Research Council, 1948 Howlett, O'Connor, Sadusk, Swift, and Beardsley, 1949; Steenken, 1949; Tucker, 1949; Lotte and Poussier, 1953) that there is a definite, and direct, relationship between initial clinical condition, particularly with regard to the extent of cavitation, and the subsequent emergence of resistant organisms. Comparisons which do not take account of this relationship will tend to exaggerate any clinical significance there may be in the emergence of drug-resistant organisms. Because patients with extensive cavitation usually develop drug resistance, whereas those with little or no cavitation tend to retain sensitive cultures, it is difficult, even in a large-scale trial of a drug which is being given alone, to assemble numbers which are adequate to compare patients with resistant and with sensitive organisms in each cavitation category. Again, a large proportion of patients receiving anti-tuberculosis chemotherapy begin to yield negative cultures soon after the start of treatment, thus further reducing the numbers available for a comparison of equally ill patients with resistant and with sensitive cultures.
In the present report, the absence of any clear disadvantage resulting from the development of isoniazid resistance may also be due to the short period of observation. For the majority of patients it was, however, undesirable on ethical grounds to stipulate a long period of treatment with a single relatively untried drug without allowing the clinician to change chemotherapy or to undertake collapse measures or resection when necessary for the patient. These essential provisos illustrate a practical difficulty in assessing the efficacy of any prescribed treatment over a protracted period. Changes of regime occur for a wide variety of reasons, ranging from very satisfactory progress to a most disappointing response which demands further measures. The patients who remain on their original prescribed treatment become a progressively more and more selected group.
Although in the present trial the period of observation was short, it was long enough to allow a study of the suggestion of a number of other investigators (Joiner and others, 1952; Coates and others, 1953; Gemez-Rieux, 1953 ) that there are immediate adverse clinical and bacteriological responses to the emergence of isoniazid-resistant organisms. If, in the present trial, such responses had occurred in a large proportion of the patients who developed resistance, the analyses of the timing of the clinical and bacteriological changes should have revealed them, even within the available period of observation.
The " fall and rise " phenomenon, namely a decrease in the bacterial population while cultures remain sensitive, followed by an increase after the emergence of drug-resistant strains, was studied for streptomycin by Mitchison (1950) . The reports of Joiner and others (1952) , Coates and others (1953) , Wallace, Stewart, Turnbull, and Crofton (1954) , and Widelock and Robins (1954) suggest that the development of isoniazid resistance is similarly associated in some patients with a diminution in the suppressive effect of the drug on bacterial multiplication. It is thus of particular interest that the present data have not yielded evidence that the " fall and rise " phenomenon occurs frequently. However, it is possible that the basis of assessment of the bacterial content of the sputum in the present trial was not sufficiently sensitive to detect any such effect.
The type of disease studied may also introduce a difficulty in investigations of the clinical significance of bacterial resistance. In the first controlled trial of streptomycin in pulmonary tuberculosis, which was restricted to a very acute, extensive form of the disease, there was a clear contrast between the early radiographic improvement shown by most of the patients on streptomycin and rest in bed and the early radiographic deterioration shown by most of those treated only with rest in bed (Medical Research Council, 1948) . These conditions offered a good opportunity to observe whether bacterial resistance was of clinical significance, because patients on ineffective treatment tended to deteriorate. If, however, less acute disease is studied, as in the present trial, a considerable proportion of patients would be expected to improve if treated with bed-rest alone. They would also be expected to improve when receiving bed-rest plus chemotherapy which was no longer effective due to bacterial resistance. Any differences between such a group of patients and a group receiving effective chemotherapy would be much less easy to demonstrate, because the comparison would be in terms of degrees of improvement rather than in terms of a contrast between improvement and deterioration. It will be appreciated that, with less acute disease, further improvement in a patient on chemotherapy after the development of bacterial resistance to the drug is not necessarily evidence of its continued clinical effectiveness. Thus, although the present report provides no adequate evidence that the development of isoniazid resistance in itself leads to a loss of clinical effectiveness of the drug, this may be due in part to the difficulties which have just been discussed and which are inherent in the analysis of these data. While, therefore, it would be wrong to conclude that the drug has necessarily remained fully effective, the analysis fails to show any substantial early loss in clinical effectiveness of isoniazid, due directly to the development of bacterial resistance.
There are, in addition, other considerations in assessing the clinical significance of the emergence of isoniazid-resistant strains. There is evidence that patients with streptomycin-resistant organisms are not protected against the development of isoniazid resistance by treatment with streptomycin plus isoniazid (Medical Research Council, 1953a) and that patients with P.A.S.-resistant organisms are not protected against the development of streptomycin resistance by treatment with streptomycin plus P.A.S. (Medical Research Council, 1953c) nor against the development of isoniazid resistance by treatment with isoniazid plus P.A.S. (Medical Research Council, 1955) . It would be of value to know whether, in patients with isoniazidresistant organisms, isoniazid in combination with another drug, for example, streptomycin or P.A.S., would no longer prevent the emergence of strains resistant to the second drug. This would indicate the relevance of the development of isoniazid resistance to the chemotherapy which the individual patient might need at a later date.
Bacilli highly resistant to isoniazid often have a lowered pathogenicity to guinea-pigs and sometimes to mice (Barnett and others, 1953; Barry and others, 1953; Middlebrook and Cohn, 1953; Meissner, 1954; Mitchison, 1954) . If a proportion of resistant organisms was of lowered pathogenicity in man, then the development of resistance might result in a tendency towards clinical improvement, even though the isoniazid was no longer effective in killing or suppressing the growth of the resistant bacilli. However, definite information on the pathogenicity of resistant strains in man is still lacking. If, as has been the case with streptomycinresistant strains (Tinne and Henderson, 1950; Harold, 1951; Medical Research Council, 1953a; Thomas, Borthwick, Home, and Crofton, 1954) , and with P.A.S.-resistant strains (Medical Research Council, 1953b; Thomas and others, 1954) , reports appear of patients newly infected with strains highly resistant to isoniazid, then the retention of some pathogenicity by such strains in man, and, as a consequence, their importance to public health will be established. Katz, Storey, and McCormick (1954) have reported a case of tuberculous pneumonia apparently due to infection with a strain resistant to streptomycin, isoniazid, and P.A.S., and fully pathogenic to the guinea-pig.
It must be remembered finally that throughout the present report the development of isoniazid resistance has been identified with the appearance of a resistant result to a sensitivity test undertaken at two months, using the Medical Research Council technique (1953b) . Pyle (1947) and Colwell, Pitner, and Moravec (1951) have shown for streptomycin, and Stewart (1954) has shown for isoniazid, that even though a test has given a resistant result, the resistant organisms may be in a minority in the tested specimen. Also, even when resistant organisms are present in the sputum, portions of the lungs which do not communicate with the bronchus may contain sensitive strains (Canetti and Saenz, 1951) . Thus over a three-month period any loss of effectiveness of the drug or any alteration in bacterial pathogenicity may in some patients relate to only a small proportion of the bacterial population and so be clinically inapparent in these patients.
In conclusion, this analysis has shown an important association between the favourable progress of patients under treatment with isoniazid alone and the early disappearance of tubercle bacilli from the sputum; patients who continue to have positive cultures are relatively at a disadvantage, whether the strains are sensitive or resistant to isoniazid.
There is much less difference between the progress of patients with sensitive and with resistant strains, when account has been taken of the influence of the extent of initial cavitation upon the development of resistance.
It should be emphasized that, although the clinical consequences of the emergence of isoniazidresistant organisms remain uncertain, the development of isoniazid resistance must be regarded as an important event. By virtue of the association between resistance and clinical progress, it provides evidence that the patient is suffering from a form of the disease which is not responding well to treatment with isoniazid alone. Thus the development of bacterial resistance to isoniazid is a sign of prognostic value.
This report illustrates the complexities inherent in assessing the clinical significance of bacterial resistance. As it is possible that the development of isoniazid resistance is a direct disadvantage to the patient in some way which has not been demonstrated by this analysis, it would be wise to continue to regard the development of isoniazid resistance as indicating some loss of clinical effectiveness of the drug, and also as constituting a potential risk to public health. Isoniazid should therefore be used only with other anti-tuberculosis drugs in combinations which are effective both in suppressing tubercle bacilli in the sputum and in preventing the emergence of isoniazid-resistant strains.
SUMMARY AND CONCLUSIONS
To investigate the clinical significance of the development of bacterial resistance to isoniazid, a study has been made of the progress of 234 patients with pulmonary tuberculosis, who were treated with isoniazid alone (100 mg. twice daily) for three months. The patients were classified, from the bacteriological findings at the end of two months, into groups of 91 with negative cultures, 58 with strains sensitive to isoniazid, 47 with moderately resistant strains, and 38 with strongly resistant strains.
These bacteriological findings were first related to the clinical characteristics of the patients at the start of treatment. Patients in poor general condition, or with high degrees of pyrexia, high sedimentation rates, or extensive cavitation were culture-positive at the end of two months more frequently than those with more favourable clinical characteristics at the start of treatment. In contrast, the emergence of isoniazid-resistant organisms was related only to the extensiveness of initial cavitation. These findings make it essential, when studying the clinical significance of isoniazid resistance, to restrict comparisons to patients with the same degree of initial cavitation.
Patients who had negative cultures at the end of two months showed on the average greater clinical progress after three months' treatment than patients with positive cultures at two months.
Thus, when standardized for differences in extent of initial cavitation, the percentages with radiographic improvement at the end of three months were 75% for the negative group and 50% for the positive group. The corresponding figures for patients whose sedimentation rates fell to normal (10 mm. or less) from a level of 21 mm. or more at the start of treatment were 35% and 19%.
There was much less difference in clinical progress at the end of three months between the patients with sensitive and the patients with resistant strains. The standardized percentages showing radiographic improvement were 55% for the sensitive and 46% for the resistant group. The corresponding figures for the lowering of the sedimentation rate were 21% and 16%. Further investigation suggests that even these differences may not be a direct consequence of the development of bacterial resistance, since the radiographic improvements and deteriorations were evenly distributed throughout the three-month period. It is therefore possible that relatively poor clinical progress and the development of bacterial resistance are both characteristics of patients with a particular host response or type of disease.
Similar studies of the bacterial content of the sputum show a considerable benefit at three months to the sensitive group, 27% having specimens positive on direct examination compared with 65% for the resistant group. Again further analyses yield no evidence that this difference arose from changes consequent upon the development of resistance.
The complex problems involved in studying the clinical significance of drug resistance are discussed, and the limitations inherent in the data, even when obtained from large numbers of patients, are stressed.
It is concluded that the early disappearance of tubercle bacilli from the sputum is an important sign of favourable progress of patients treated with isoniazid alone. The study of possible clinical disadvantages due directly to the development of isoniazid resistance is inconclusive. Nevertheless, because isoniazid resistance tends to occur in disease which is pursuing a relatively unfavourable course, its development is an adverse prognostic sign.
As it is possible that isoniazid resistance is a direct disadvantage to the patient in some way which has not been demonstrated in this study, it would be wise to continue to regard the development of isoniazid resistance as indicating some loss of clinical effectiveness of the drug, and also as constituting a potential risk to public health. Isoniazid should therefore be given only in combination with suitable dosages of other drugs.
APPENDIX
The following procedure was adopted for assigning doubtfully resistant results of isoniazid-sensitivity tests at two months to " probably resistant" and " probably sensitive" categories on the basis of the bacteriological findings at three and, if necessary, four months. 
